Results 271 to 280 of about 19,188,679 (307)
Some of the next articles are maybe not open access.
EP617 Second line treatment in metastatic uterine pecoma
International Journal of Gynecological Cancer, 2019Introduction/Background Uterine perivascular epithelioid cell tumors (PEComas) are rare neoplasms associated with upregulation of the mTOR pathway, frequently through inactivation of TSC1/TSC2. The treatment of advanced and metastatic PEComas is challenging, especially after progression on mTOR inhibitors.
Liapi, A +6 more
openaire +2 more sources
[Second line treatments of cancers of the ovary].
La Revue du praticien, 1997Ovarian adenocarcinomas are among the most chemosensitive tumors. Platinum derivatives are the most efficient agents. The role of the second-line therapy is either to treat the relapse (salvage therapy), or to prevent it (consolidation therapy). The most active agents in the salvage setting are new molecules: taxoids, vinorelbin, topotecan.
J M, Extra, P H, Cottu
openaire +1 more source
Advancements in second-line treatment research for hepatocellular carcinoma
Clinical and Translational OncologyHepatocellular carcinoma (HCC) is one of the most common malignant tumors, characterized by high incidence and mortality rates. Due to its insidious onset, most patients are diagnosed at an advanced stage, often missing the opportunity for surgical resection. Consequently, systemic treatments play a pivotal role.
Ruirui Sun +4 more
openaire +2 more sources
Comparative effectiveness of second‐line treatments for epileptic spasms
EpilepsiaAbstract Objective This study was undertaken to evaluate the response to second treatments for infantile epileptic spasms syndrome (IESS). Methods Infants aged 2–24 months with IESS were prospectively enrolled in the ...
Kristen Barbour +21 more
openaire +2 more sources
Second line therapies for the treatment of gastrointestinal stromal tumor
Current Opinion in Oncology, 2007Most gastrointestinal stromal tumors eventually acquire resistance to imatinib mesylate. This review focuses on recent progress on management of patients whose disease progresses on the standard dose of imatinib.Approximately 30% of patients failing standard-dose imatinib achieve disease stabilization with high-dose imatinib, but objective responses ...
openaire +2 more sources
[Second-line treatments for Parkinson's disease].
La Revue du praticienFollowing an initial phase characterized by a good response to dopaminergic therapies, Parkinson's disease progresses toward a stage marked by motor complications-notably motor fluctuations and dyskinesias. When the optimization of oral therapy proves insufficient, the use of second-line treatments must be considered.
Guillaume, Carey, Luc, Defebvre
openaire +1 more source
Treatment-Free Remission After Second-Line Nilotinib Treatment
Annals of Internal Medicine, 2018François-Xavier, Mahon +1 more
openaire +4 more sources
An Approximate Line Attractor in the Hypothalamus Encodes an Aggressive State
Cell, 2023Aditya Nair +2 more
exaly